New scan lights up hidden gut tumors
NCT ID NCT06091748
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 3 trial tested a special PET-CT scan using a radioactive tracer called gallium-68 DOTATOC to find neuroendocrine tumors in the stomach, intestines, and pancreas. 69 adults with confirmed or suspected tumors received the scan. The goal was to see how accurately the scan could detect these tumors. Results show the scan is a promising tool for diagnosis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Gallium-68 DOTATOC (a radioactive tracer for PET-CT imaging)
- What this could lead to
- If successful, this imaging method could become a standard way to detect and confirm neuroendocrine tumors in the digestive system, helping guide treatment decisions.
- What could go wrong
- This is a small, single-arm study with 69 participants, so results may not apply to all patients. The scan involves radiation exposure, though at low levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.